Document Detail


Solifenacin at 3 years: a review of efficacy and safety.
MedLine Citation:
PMID:  18654073     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Now on the market in the United States for almost 3 years and available in 48 countries worldwide, solifenacin 5 mg or 10 mg once daily continues to demonstrate a profile of safety and efficacy as a treatment for incontinence, urgency, and other symptoms of OAB. More than 2.2 million patients have been treated worldwide with solifenacin. Safety and efficacy data across numerous studies in several thousand patients, along with flexible dosing, support the use of this agent as a first-line antimuscarinic treatment for OAB. Data from large randomized controlled trials such as VENUS and STAR show statistically significant superiority compared with placebo and improved outcomes over those achieved with tolterodine ER 4 mg. Solifenacin is an agent of choice for OAB-related incontinence, with more than 50% of incontinent patients reporting no incontinence episodes after 12 weeks of solifenacin therapy. In addition to improved efficacy, solifenacin offers good tolerability with a low incidence of side effects. Once-daily, flexible dosing with this agent provides 24-hour control of OAB symptoms and significantly increases warning time (the period from onset of urgency to voiding), which may also increase a patient's chance of avoiding episodes of incontinence.
Authors:
Richard S Pelman; James P Capo; Sergio Forero-Schwanhaeuser
Related Documents :
19697083 - The management of cough: a clinical year in review.
24572563 - Reviews examining sugar-sweetened beverages and body weight: correlates of their qualit...
21974773 - Hand warmer related corrosive injury.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Postgraduate medicine     Volume:  120     ISSN:  1941-9260     ISO Abbreviation:  Postgrad Med     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-07-25     Completed Date:  2008-10-21     Revised Date:  2009-02-12    
Medline Journal Info:
Nlm Unique ID:  0401147     Medline TA:  Postgrad Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  85-91     Citation Subset:  AIM; IM    
Affiliation:
Bellevue Urology Associates, Bellevue, WA 98004, USA. rpelman@bellevueurology.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Aged, 80 and over
Drug Administration Schedule
Humans
Middle Aged
Muscarinic Antagonists / pharmacokinetics,  therapeutic use*
Quinuclidines / pharmacokinetics,  therapeutic use*
Tetrahydroisoquinolines / pharmacokinetics,  therapeutic use*
Treatment Outcome
Urinary Bladder, Overactive / drug therapy*,  etiology,  physiopathology
Chemical
Reg. No./Substance:
0/Muscarinic Antagonists; 0/Quinuclidines; 0/Tetrahydroisoquinolines; 0/quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate
Comments/Corrections
Comment In:
Postgrad Med. 2008 Nov;120(4):107-8   [PMID:  19020373 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Human papillomavirus, cervical cancer, and the vaccines.
Next Document:  Dispelling the myths about omega-3 fatty acids.